Theragnostics

Theragnostics is a radiopharmaceutical company whose mission is to improve the lives of cancer patients with novel agents for molecular imaging and therapy.

[Theragnostics @Theragnostics]

https://t.co/F5KdoidmXH.

[Theragnostics @Theragnostics]

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport. #GBM #Cancer #cancerawareness #radiopharmaceuticals #glioblastoma

[Theragnostics @Theragnostics]

@Theragnostics today announces licensing agreement for development and commercialization of one-step PET radiopharmaceuticals.

https://t.co/XV5d9C2jYv

#biotech #oncology #radiopharmaceuticals #cancer #developement #commercialisation @Novartis @Advancedacceleratorapplications

[Theragnostics @Theragnostics]

@Theragnostics is delighted to announce the appointments of key drug development experts Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to our Board as we prepare for the next stage of growth.
Read more: https://t.co/FyXoQdsIOo
#biotech #oncology #cancer

[Theragnostics @Theragnostics]

Today we are delighted to announce our research collaboration with Essen University Hospital
https://t.co/m844H9BBP9
#theragnostics #cancer #parpi

[Theragnostics @Theragnostics]

Theragnostics is excited to share how we are utilizing PARP inhibitors to target cancer cells and progress the field cancer research!

[Theragnostics @Theragnostics]

Great to see increasing interest in the next generation of radiopharmaceuticals” with a link to this article? RayzeBio debuts with $45M to target tumors with radiopharmaceuticals: https://t.co/v4ysvxIxR4

[Theragnostics @Theragnostics]

We are proud to support #OvarianCancerAwarenessMonth as we continue to work on the development of our targeted #radionuclide THG-009. Spotting signs and symptoms earlier is crucial. @OvarianCancerUK explains what you should be looking out for:
https://t.co/1DdVIeXBij

[Theragnostics @Theragnostics]

Pleased to announce our deal with Summit Biomedical Imaging LLC #theragnostics #cancer #parpi
https://t.co/eTBZUtHS48

[Theragnostics @Theragnostics]

Theragnostics is proud to announce our collaboration with the ‘Next generation molecular imaging and therapy with radionuclide’ (MITHRAS) programme currently launching in the UK.
https://t.co/zyvivLiX0O

[Theragnostics @Theragnostics]

The Theragnostics team are on lock down but still supporting Brain Tumour Research today with #WearAHatDay.
Please donate here: https://t.co/r5JNZdbGjg
#braintumour #braincancer #cancerresearch
(Thanks to Daniel Tiller for helping with the collage!) @braintumourrsch

[Theragnostics @Theragnostics]

@Theragnostics
CEO Greg Mullen will be attending the Prostate Cancer PSMA Masterclass this week at @ExploreWelcome in partnership with @UCL.
More information: https://t.co/7defCCjWnH
Register here: https://t.co/yfW4DyETfi
#radiopharmaceuticals #oncology #WellcomeTrust #PSMA

[Theragnostics @Theragnostics]

Theragnostics has an exciting new position to fill in our US office:
https://t.co/EwCW1KfpZQ

[Theragnostics @Theragnostics]

@Theragnostics management team have arrived in San Francisco to attend #JPM2020. CEO Greg Mullen and COO Gareth Smith will be attending and hosting meetings at JPM in SF. Reach out to us!#PARPi #radiopharmaceuticals #oncology #biotech

https://t.co/M9UkCkuAA5

[Theragnostics @Theragnostics]

CEO Greg Mullen will be speaking on the panel “Meeting Biotech Rising Stars” at #Genesis Conference

[Theragnostics @Theragnostics]

We are working hard to develop and perfect our single step cold kit Prostate Cancer Diagnostic, #PSMA. We strive to reach more people by making Prostate Diagnostic Imaging more accessible . See how at
https://t.co/HzaSFqaDtn

[Theragnostics @Theragnostics]

Theragnostics would like to say thanks to our Director of Project Management and Business Development, Aaron Block, for showing his support for #prostatecancerawarenessmonth with an impressive mustache. #Movember

[Theragnostics @Theragnostics]

#Theragnostics strengthens leadership team with two key appointments: Chris Sterling appointed as Non-Executive Director. #Radiopharmaceutical #drugdevelopment expert Dr Daniel Stevens joins as Chief Medical Officer

https://t.co/OBZNFH0gQN

[Theragnostics @Theragnostics]

18F-PARPi Phase I trial data in head & neck cancer goes into the public domain. Just the beginning for rPARPi. #Theragnostics
#rPARPi
#Clinicaltrials

https://t.co/JsLZAceuL7

[Ignition Law @IgnitionLaw]

Fantastic news from our friends at @Theragnostics who have partnered with @GEHealthcare for late stage PSMA diagnostic for #ProstateCancer There novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. Great collab.